drugset / Trial / NCT05892393
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Phase 1
Recruiting
20 enrolled
University of California, San Francisco
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
This phase I trial tests the safety of \[89Zr\]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. \[89Zr\]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. \[89Zr\]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and \[89Zr\]DFO-YS5 PET scans may improve detection of multiple myeloma.
Timeline
- Start
- 2023-06-16
- Primary completion
- 2026-08-01
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zirconium Zr 89-DFO-YS5 | Diagnostic / imaging agent | — | Intravenous |